Efficacy and Safety of Pyronaridine-Artesunate plus Single-Dose Primaquine for the Treatment of Malaria in Western Cambodia

Antimicrob Agents Chemother. 2019 Sep 23;63(10):e01273-19. doi: 10.1128/AAC.01273-19. Print 2019 Oct.

Abstract

This single-arm trial (n = 104) in western Cambodia showed high efficacy for 3-day treatment with pyronaridine-artesunate plus single-dose primaquine in Plasmodium falciparum malaria. Day 42 PCR-adjusted adequate clinical and parasitological response (ACPR) was 98.3% (58/59) (95% confidence interval [CI], 90.9 to 100.0) in Trapeng Chau in Kampong Speu and 100% (41/41) (95% CI, 91.4 to 100) in Veal Veng in Pursat; 80.6% (83/103) of the patients had P. falciparum with drug resistance molecular markers. For Plasmodium vivax malaria, pyronaridine-artesunate day 28 ACPR was 98.3% (59/60) (95% CI, 91.1 to 100) and 100% (60/60) (95% CI, 94.0 to 100), respectively. (This study is registered in the Australian New Zealand Clinical Trials Registry [ANZCTR] under reference no. ACTRN12618001999224.).

Keywords: Cambodia; Plasmodium falciparum; Plasmodium vivax; antimalarial agents; artemisinin; drug resistance; malaria; pyronaridine-artesunate.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Antimalarials / adverse effects
  • Antimalarials / therapeutic use
  • Artesunate / adverse effects*
  • Artesunate / therapeutic use*
  • Cambodia
  • Child
  • Drug Resistance
  • Female
  • Humans
  • Malaria / drug therapy*
  • Male
  • Middle Aged
  • Naphthyridines / adverse effects*
  • Naphthyridines / therapeutic use*
  • Plasmodium vivax / drug effects
  • Plasmodium vivax / pathogenicity
  • Primaquine / adverse effects*
  • Primaquine / therapeutic use*
  • Young Adult

Substances

  • Antimalarials
  • Naphthyridines
  • Artesunate
  • Primaquine
  • pyronaridine

Associated data

  • ANZCTR/ACTRN12618001999224